India Coronavirus Dispatch: A look inside Serum's manufacturing facility

Falling weekly death toll, false claims about Covid-19 vaccines, how long vaccine-derived antibody protection lasts-news relevant to India's fight against Covid-19

serum institute, coronavirus, covid, vaccine, pharma
Vaccines made by SII are accredited by the World Health Organization
Bharath Manjesh New Delhi
3 min read Last Updated : Feb 01 2021 | 2:58 PM IST
A look inside Serum Institute of India's manufacturing facility

Pune-based Serum Insititute of India (SII), which manufactures Covishield, is the world's largest vaccine maker by volume. Founded by Cyrus Poonawalla in 1966, the firm has sold over 1.5 billion doses of vaccines including for Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Vaccines made by SII are accredited by the World Health Organization. They are being used in around 170 countries around the world in their national immunisation programs. A report in The Hindu provides a look inside the vaccine giant's manufacturing facility. See here

Weekly death toll less than 1,000 for the first time since May last year

For the first time since the first week of May in 2020, the country's weekly death toll from Covid-19 dropped below 1,000. The toll of fatalities in January this year was less than half of that in December and the lowest in eight months, according to a report in The Times of India.

The tally of fresh infections of the novel coronavirus is also on a downward trajectory. The count in January fell below 500,000 to 4,71,282—the lowest monthly tally since June last year. Last week, the country had reported less than 100,000 infections for the first time since the June 15-21 week. Weekly infection tally is now less than 14% of the number seen at the height of the pandemic, the report said. Read more here

False claims about Covid-19 vaccines

Various false claims about Covid-19 vaccines are doing the rounds on social media. This report in the BBC brings you some widely-shared ones.

A claim that did the rounds on social media was the vaccine will lead to impotency. There is no evidence to suggest this and India's top drug regulator called the claim "absolute rubbish". Another claim says that the vaccine is free in India, while in both the US and in England you will pay. This is not true. The US government has said that Covid vaccines will be free, and the charge for administering the jab will be covered either through insurance or by a special Covid relief fund. 

In England as well, which is part of the UK's National Health Service, where there are no charges for vaccines. Conspiracy theories have also falsely claimed that the vaccines contain microchips. Read more here

How lack of technology became a hurdle to justice after pandemic hit

In April last year, the Supreme Court directed that court proceedings be held through video-conferencing as a precaution against Covid-19. But, the country's justice systems were not fully equipped to tackle the emergency, according to a report in IndiaSpend. Only 6 out of 10 jails in the country had video conferencing facilities right before the pandemic struck. Less than half of all states and Union Territories had the facilities in 90% of their jails, the article said, citing a report from Tata Trusts. Read more here

How long does vaccine-derived antibody protection last?

It is not clear if protection from antibodies can last more than six months, according to a report in The Hindu. The promoters of Bharat Biotech and scientists at the ICMR say the strength of a vaccine depends on it being a "whole-inactivated virus". That means a larger surface area of the virus is visible to the body's immune system and in turn a wider range of antibodies are produced. But, antibodies from all vaccines so far are largely aimed at the spike protein. Therefore, more does not necessarily mean better. Read more here

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story